Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis
By
Emily S. Acker
Gabriela Martin Gonzalez
Dylan Davie
Ratna B. Basak
April 20, 2026
Clinical Scorecard: Systemic Corticosteroids as an Adjunct Therapy in Pediatric Orbital Cellulitis: A Comprehensive Review and Meta-Analysis
At a Glance
Category Detail
Condition Key Mechanisms Adjunctive systemic corticosteroids may reduce inflammation but carry risks of worsening infection and adverse outcomes. Target Population Care Setting
Key Highlights
Corticosteroids did not significantly reduce hospital length of stay. Increased risks of surgical intervention and PICU admission associated with corticosteroid use. Higher rates of 30-day readmission observed in corticosteroid group. Evidence quality was low to moderate due to observational study designs. Need for high-quality randomized controlled trials to clarify corticosteroid role and address gaps in evidence. Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Be aware of potential increased risks associated with corticosteroid use, including surgical intervention and readmission. Further research is needed to clarify the role of corticosteroids in pediatric orbital cellulitis. Patient & Prescribing Data
Pediatric patients under 21 years with orbital cellulitis
Corticosteroids may not provide clinical benefits and could increase adverse outcomes.
Clinical Best Practices
Consider the risks versus benefits of corticosteroid use in pediatric orbital cellulitis. Adhere to evidence-based guidelines for antibiotic therapy. Ensure close monitoring of patients for complications during hospitalization. Encourage interdisciplinary collaboration in managing pediatric patients with orbital cellulitis. References
